Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MK-5890 alone and with pembrolizumab in advanced solid tumors
NL-OMON52475Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of omaveloxolone in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and 1 more (8 arms), sponsored by Merck & Co. Primary endpoints: Number of participants with a dose-limiting toxicity, Number of participants with at least 1 adverse event and 1 more. Started Jun 2018; status: recruiting.
02
Drugs
omaveloxolone
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON52475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52475.